“Whereas what we’re proposing is placing them in industrial units or in the basement of hospitals or production centers. We can then produce the drugs exactly where they needed, and be able to reduce the reliance on these centralized production sites,” he added.
He believes competitors are constrained by existing technology: “Most other approaches are based on linear, accelerated technology, whereas what we’re doing is essentially taking a very high TRL core architecture and putting in 2020 physics, where the ceiling is quite high in terms of performance. So we’re just at the start of what’s achievable with this,” he said.